Mucosal melanoma

Epidemiology, biology and treatment

Kristen R. Spencer, Janice Mehnert

Research output: Chapter in Book/Report/Conference proceedingChapter

26 Citations (Scopus)

Abstract

Mucosal melanoma is an exceedingly rare variant of cutaneous melanoma that, due to its rarity, is poorly described and infrequently studied. Primary sites of origin include the head and neck, anorectum and vulvovaginal regions. It is uniquely different from cutaneous melanoma with respect to epidemiology, etiology, pathogenesis and prognosis. The etiology and pathogenesis remain unclear. Unlike cutaneous melanoma, exposure to UV light is not an apparent risk factor. Furthermore, distinct molecular features including a lower incidence of BRAF oncogene mutations but a higher incidence of KIT oncogene mutations suggest divergent genetic etiologies. Mucosal melanomas generally present at a later stage, are more aggressive and carry a worse prognosis regardless of the stage at diagnosis. Establishing standardized treatment guidelines has been challenging due to the rarity of the disease. Early detection provides the best chance at survival but is often difficult due to anatomic location. Surgery remains the primary therapeutic intervention if complete resection is technically feasible given the anatomic location. Radiotherapy may be used to achieve local control when resection is not feasible, or adjuvantly to enhance locoregional control, but most studies have failed to demonstrate an improvement in overall survival. There are no consensus guidelines on the optimal systemic therapy, and regimens are often extrapolated from data based on therapies used to treat advanced cutaneous melanoma. Clinical trials, particularly utilizing newer targeted therapies and immunotherapies, are investigating novel treatment approaches.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherKluwer Academic Publishers
Pages295-320
Number of pages26
DOIs
StatePublished - Jan 1 2016

Publication series

NameCancer Treatment and Research
Volume167
ISSN (Print)0927-3042

Fingerprint

Melanoma
Epidemiology
Skin
Oncogenes
Therapeutics
Guidelines
Mutation
Incidence
Ultraviolet Rays
Immunotherapy
Neck
Radiotherapy
Head
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Spencer, K. R., & Mehnert, J. (2016). Mucosal melanoma: Epidemiology, biology and treatment. In Cancer Treatment and Research (pp. 295-320). (Cancer Treatment and Research; Vol. 167). Kluwer Academic Publishers. https://doi.org/10.1007/978-3-319-22539-5_13
Spencer, Kristen R. ; Mehnert, Janice. / Mucosal melanoma : Epidemiology, biology and treatment. Cancer Treatment and Research. Kluwer Academic Publishers, 2016. pp. 295-320 (Cancer Treatment and Research).
@inbook{c63cf9ef3f72474eb86117942faa70ae,
title = "Mucosal melanoma: Epidemiology, biology and treatment",
abstract = "Mucosal melanoma is an exceedingly rare variant of cutaneous melanoma that, due to its rarity, is poorly described and infrequently studied. Primary sites of origin include the head and neck, anorectum and vulvovaginal regions. It is uniquely different from cutaneous melanoma with respect to epidemiology, etiology, pathogenesis and prognosis. The etiology and pathogenesis remain unclear. Unlike cutaneous melanoma, exposure to UV light is not an apparent risk factor. Furthermore, distinct molecular features including a lower incidence of BRAF oncogene mutations but a higher incidence of KIT oncogene mutations suggest divergent genetic etiologies. Mucosal melanomas generally present at a later stage, are more aggressive and carry a worse prognosis regardless of the stage at diagnosis. Establishing standardized treatment guidelines has been challenging due to the rarity of the disease. Early detection provides the best chance at survival but is often difficult due to anatomic location. Surgery remains the primary therapeutic intervention if complete resection is technically feasible given the anatomic location. Radiotherapy may be used to achieve local control when resection is not feasible, or adjuvantly to enhance locoregional control, but most studies have failed to demonstrate an improvement in overall survival. There are no consensus guidelines on the optimal systemic therapy, and regimens are often extrapolated from data based on therapies used to treat advanced cutaneous melanoma. Clinical trials, particularly utilizing newer targeted therapies and immunotherapies, are investigating novel treatment approaches.",
author = "Spencer, {Kristen R.} and Janice Mehnert",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-22539-5_13",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Kluwer Academic Publishers",
pages = "295--320",
booktitle = "Cancer Treatment and Research",
address = "Netherlands",

}

Spencer, KR & Mehnert, J 2016, Mucosal melanoma: Epidemiology, biology and treatment. in Cancer Treatment and Research. Cancer Treatment and Research, vol. 167, Kluwer Academic Publishers, pp. 295-320. https://doi.org/10.1007/978-3-319-22539-5_13

Mucosal melanoma : Epidemiology, biology and treatment. / Spencer, Kristen R.; Mehnert, Janice.

Cancer Treatment and Research. Kluwer Academic Publishers, 2016. p. 295-320 (Cancer Treatment and Research; Vol. 167).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Mucosal melanoma

T2 - Epidemiology, biology and treatment

AU - Spencer, Kristen R.

AU - Mehnert, Janice

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Mucosal melanoma is an exceedingly rare variant of cutaneous melanoma that, due to its rarity, is poorly described and infrequently studied. Primary sites of origin include the head and neck, anorectum and vulvovaginal regions. It is uniquely different from cutaneous melanoma with respect to epidemiology, etiology, pathogenesis and prognosis. The etiology and pathogenesis remain unclear. Unlike cutaneous melanoma, exposure to UV light is not an apparent risk factor. Furthermore, distinct molecular features including a lower incidence of BRAF oncogene mutations but a higher incidence of KIT oncogene mutations suggest divergent genetic etiologies. Mucosal melanomas generally present at a later stage, are more aggressive and carry a worse prognosis regardless of the stage at diagnosis. Establishing standardized treatment guidelines has been challenging due to the rarity of the disease. Early detection provides the best chance at survival but is often difficult due to anatomic location. Surgery remains the primary therapeutic intervention if complete resection is technically feasible given the anatomic location. Radiotherapy may be used to achieve local control when resection is not feasible, or adjuvantly to enhance locoregional control, but most studies have failed to demonstrate an improvement in overall survival. There are no consensus guidelines on the optimal systemic therapy, and regimens are often extrapolated from data based on therapies used to treat advanced cutaneous melanoma. Clinical trials, particularly utilizing newer targeted therapies and immunotherapies, are investigating novel treatment approaches.

AB - Mucosal melanoma is an exceedingly rare variant of cutaneous melanoma that, due to its rarity, is poorly described and infrequently studied. Primary sites of origin include the head and neck, anorectum and vulvovaginal regions. It is uniquely different from cutaneous melanoma with respect to epidemiology, etiology, pathogenesis and prognosis. The etiology and pathogenesis remain unclear. Unlike cutaneous melanoma, exposure to UV light is not an apparent risk factor. Furthermore, distinct molecular features including a lower incidence of BRAF oncogene mutations but a higher incidence of KIT oncogene mutations suggest divergent genetic etiologies. Mucosal melanomas generally present at a later stage, are more aggressive and carry a worse prognosis regardless of the stage at diagnosis. Establishing standardized treatment guidelines has been challenging due to the rarity of the disease. Early detection provides the best chance at survival but is often difficult due to anatomic location. Surgery remains the primary therapeutic intervention if complete resection is technically feasible given the anatomic location. Radiotherapy may be used to achieve local control when resection is not feasible, or adjuvantly to enhance locoregional control, but most studies have failed to demonstrate an improvement in overall survival. There are no consensus guidelines on the optimal systemic therapy, and regimens are often extrapolated from data based on therapies used to treat advanced cutaneous melanoma. Clinical trials, particularly utilizing newer targeted therapies and immunotherapies, are investigating novel treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=84948798280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948798280&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-22539-5_13

DO - 10.1007/978-3-319-22539-5_13

M3 - Chapter

T3 - Cancer Treatment and Research

SP - 295

EP - 320

BT - Cancer Treatment and Research

PB - Kluwer Academic Publishers

ER -

Spencer KR, Mehnert J. Mucosal melanoma: Epidemiology, biology and treatment. In Cancer Treatment and Research. Kluwer Academic Publishers. 2016. p. 295-320. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-319-22539-5_13